ORAVERSE SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

PHENTOLAMINE MESYLATE

Доступна с:

SEPTODONT

код АТС:

V03AB36

ИНН (Международная Имя):

PHENTOLAMINE

дозировка:

0.4MG

Фармацевтическая форма:

SOLUTION

состав:

PHENTOLAMINE MESYLATE 0.4MG

Администрация маршрут:

SUBMUCOSAL

Штук в упаковке:

10X1.7ML/50X1.7ML

Тип рецепта:

Prescription

Терапевтические области:

Non-Selective Alfa-Adrenergic Blocking Agents

Обзор продуктов:

Active ingredient group (AIG) number: 0107611003; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2014-02-26

Характеристики продукта

COPYRIGHT 2012 - 2013 SEPTODONT Page 1 of 17
PRODUCT MONOGRAPH
PR
ORAVERSE
PHENTOLAMINE MESYLATE INJECTION HOUSE STANDARD
PHENTOLAMINE MESYLATE INJECTION, 0.4MG/1.7ML
_ _
_ _
Alpha-adrenoreceptor blocker
_For Intraoral Submucosal Injection Only _
Sponsor: Manufacturer:
Septodont SAS Novocol Pharmaceutical of Canada, Inc.
58 Rue Du Pont De Creteil 25 Wolseley Court,
Saint-Maur Des Fosses Cambridge, Ontario,
France 94100 N1R 6X3
DATE OF PREPARATION:
FEBRUARY 24, 2014
SUBMISSION CONTROL NO: 157450
COPYRIGHT 2012 - 2013 SEPTODONT Page 2 of 17
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................................
3
SUMMARY PRODUCT INFORMATION
....................................................................................................
3
INDICATIONS AND CLINICAL
USE..........................................................................................................
3
CONTRAINDICATIONS
...............................................................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................................................
3
ADVERSE REACTIONS
...............................................................................................................................
4
DRUG INTERACTIONS
................................................................................................................................
6
DOSAGE AND ADMINISTRATION
............................................................................................................
7
OVERDOSAGE
..............................................................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
..........................................................................................
8
STORAGE AND STABILITY
................................................................